Related Experiment Video
Updated: Jun 17, 2025
A Bright NIR-II Fluorescence Probe for Vascular and Tumor Imaging
Published on: March 17, 2023
Recent Advances in the Application of Nitro(het)aromatic Compounds for Treating and/or Fluorescent Imaging of Tumor
Kameliya Anichina1, Nikolay Lumov1,2, Ventsislav Bakov1
1Department of Organic Synthesis, University of Chemical Technology and Metallurgy, 8 Kliment Ohridski Blvd., 1756 Sofia, Bulgaria.
Abstract:
This review delves into recent advancements in the field of nitro(het)aromatic bioreductive agents tailored for hypoxic environments. These compounds are designed to exploit the low-oxygen conditions typically found in solid tumors, making them promising candidates for targeted cancer therapies. Initially, this review focused on their role as gene-directed enzyme prodrugs, which are inert until activated by specific enzymes within tumor cells. Upon activation, these prodrugs undergo chemical transformations that convert them into potent cytotoxic agents, selectively targeting cancerous tissue while sparing healthy cells. Additionally, this review discusses recent developments in prodrug conjugates containing nitro(het)aromatic moieties, designed to activate under low-oxygen conditions within tumors. This approach enhances their efficacy and specificity in cancer treatment. Furthermore, this review covers innovative research on using nitro(het)aromatic compounds as fluorescent probes for imaging hypoxic tumors. These probes enable non-invasive visualization of low-oxygen regions within tumors, providing valuable insights for the diagnosis, treatment planning, and monitoring of therapeutic responses. We hope this review will inspire researchers to design and synthesize improved compounds for selective cancer treatment and early diagnostics.
Insights
Nitro(het)aromatic bioreductive agents are advancing targeted cancer therapies by exploiting tumor hypoxia. These compounds function as prodrugs and fluorescent probes for enhanced diagnostics and treatment.
Area of Science:
- Medicinal Chemistry
- Biomedical Engineering
- Oncology
Background:
- Hypoxic microenvironments in solid tumors present unique therapeutic challenges.
- Nitro(het)aromatic compounds offer potential for targeted drug activation and imaging in low-oxygen conditions.
Purpose of the Study:
- To review recent advancements in nitro(het)aromatic bioreductive agents for hypoxic environments.
- To highlight their applications as gene-directed enzyme prodrugs, prodrug conjugates, and fluorescent probes.
- To discuss their role in targeted cancer therapy and diagnostics.
Main Methods:
- Literature review of recent research on nitro(het)aromatic compounds.
- Analysis of their mechanisms of action in hypoxic conditions.
- Evaluation of their efficacy as prodrugs and imaging agents.
Main Results:
- Nitro(het)aromatic compounds show promise as prodrugs activated in hypoxic tumors, leading to selective cytotoxicity.
- Prodrug conjugates enhance efficacy and specificity for cancer treatment.
- These compounds serve as effective fluorescent probes for visualizing hypoxic tumor regions.
Conclusions:
- Nitro(het)aromatic bioreductive agents are valuable tools for targeted cancer therapy and diagnostics.
- Further research can lead to improved compounds for selective cancer treatment and early detection.
- These agents offer a promising strategy for overcoming challenges in solid tumor treatment.
